Features of lipid metabolism and hemostasis in patients with arterial hypertension underwent a new coronavirus infection COVID-19
https://doi.org/10.18699/SSMJ20240521
Abstract
An increase in the frequency of patients with arterial hypertension (AH) seeking medical care and its more severe course after a novel coronavirus infection (NCI), COVID-19, determines the need to study possible pathogenetic mechanisms of disease progression. Aim of the study was to investigate some features of lipid metabolism and changes in hemostasis in patients with AH after NCI COVID-19. Material and methods. An analysis of the most informative indicators of lipid metabolism and hemostasis was carried out in 104 patients with AH underwent (more than 2 months ago) NCI, in comparison with 117 patients with AH, with no history of COVID-19. The study included men and women aged from 30 to 75 years. Determination of the concentration of lipids in blood serum was carried out using the photometric method on a biochemical analyzer AU 480 (Beckman Coulter, США). Hemostatic parameters were determined by the chromogenic method using an automatic hemostasis analyzer Technology Solution 190 (USA). Results and discussion. It was found that patients with AH underwent NCI had significantly higher serum levels of total cholesterol, LDL cho- lesterol, triglycerides, D-dimers, platelets and lower activated partial thromboplastin and thrombin time compared with patients without COVID-19. Conclusions. The data obtained indicate a tendency to atherogenic changes in the blood lipid profile and increased coagulation processes in patients with AH in the long-term period (more than 2 months) after suffering a NCI COVID-19.
About the Authors
E. V. Sevostyanova
Federal Research Center of Fundamental and Translational Medicine
Russian Federation
Russian Federation
Evgeniya V. Sevostyanova, candidate of medical sciences
630117, Novosibirsk, Timakova st., 2
Yu. A. Nikolaev
Federal Research Center of Fundamental and Translational Medicine
Russian Federation
Russian Federation
Yuriy A. Nikolaev, doctor of medical sciences
630117, Novosibirsk, Timakova st., 2
V. Ya. Polyakov
Federal Research Center of Fundamental and Translational Medicine
Russian Federation
Russian Federation
Vladimir Ya. Polyakov, doctor of medical sciences
630117, Novosibirsk, Timakova st., 2
I. L. Emelyanova
Federal Research Center of Fundamental and Translational Medicine
Russian Federation
Russian Federation
Irina L. Emelyanova
630117, Novosibirsk, Timakova st., 2
References
1. Malik P., Patel K., Pinto C., Jaiswal R., Tirupathi R., Pillai S., Patel U. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-A systematic review and meta-analysis. J. Med. Virol. 2022;94(1):253–262. doi: 10.1002/jmv.27309
2. Sharipova M.M., Ivkina M.V., Arkhangelskaya A.N., Gurevich K.G., Maev I.V. Features of the course of COVID-19 in patients with comorbid pathology. Meditsinskiy sovet = Medical Council. 2022;16(6):44–49. [In Russian]. doi:10.21518/2079-701X-2022-16-6-44-49
3. Huang S., Wang J., Liu F., Liu J., Cao G., Yang C., Liu W., Tu C., Zhu M., Xiong B. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens. Res. 2020;43(8):824–831. doi: 10.1038/s41440-020-0485-2
4. Tadic M., Cuspidi C., Grassi G., Mancia G. COVID-19 and arterial hypertension: Hypothesis or evidence? J. Clin. Hypertens. (Greenwich). 2020;22(7):1120–1126. doi: 10.1111/jch.13925
5. Arutjunov G.P., Tarlovskaja E.I., Arutjunov A.G., Belenkov Ju.N., Konradi A.O., Lopatin Ju.M., Rebrov A.P., Tereshchenko S.N., Chesnikova A.I., Ajrapetjan G.G. ... Jausheva E.Ju. Results of the international registry “Analysis of the dynamics of comorbid diseases in patients who have been infected with SARS-CoV-2 (ACTIVE SARSCoV-2).” Preliminary data (6 months of follow-up). Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021;26(10):4708. doi: 10.15829/1560-4071-2021-4708
6. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Boytsov S.A., Vavilova T.V., Villevalde S.V., … Yanishevsky S.N. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(3):3786. (In Russian). doi: 10.15829/1560-4071-2020-3-3786
7. Hu X., Chen D., Wu L., He G., Ye W. Low serum cholesterol level among patients with COVID-19 infection in Wenzhou. Lancet. 2020;29(342):1167–1173. doi: 10.2139/ssrn.3544826
8. Wei X., Zeng W., Su J., Wan H., Yu X., Cao X., Tan W., Wang H. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 2020;14(14):297–304. doi: 10.1016/j.jacl.2020.04.008
9. Gameil M.A., Marzouk R.E., Elsebaie A.H., Rozaik S.E. Long-term clinical and biochemical residue after COVID-19 recovery. Egypt Liver J. 2021;11(1):74. doi: 10.1186/s43066-021-00144-1
10. Wrona M., Skrypnik D. New-onset diabetes mellitus, hypertension, dyslipidaemia as sequelae of COVID-19 infection-systematic review. Int. J. Environ. Res. Public Health. 2022;19(20):13280. doi: 10.3390/ijerph192013280
11. Martínez-Martínez A.B., Torres-Perez E., Devanney N., Del Moral R., Johnson L.A., ArbonesMainar J.M. Beyond the CNS: The many peripheral roles of APOE. Neurobiol. Dis. 2020;138:104809. doi: 10.1016/j.nbd.2020.104809
12. Sorokin A.V., Karathanasis S.K., Yang Z.H., Freeman L., Kotani K., Remaley A.T. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. FASEB J. 2020;34(8):9843–9853. doi: 10.1096/fj.202001451
13. Wang X., Lei J., Li Z., Yan L. Potential effects of coronaviruses on the liver: an update. Front. Med. (Lausanne). 2021;27(8):651658. doi: 10.3389/fmed.2021.651658
14. Yıldırım Ö.T., Kaya Ş. The atherogenic index of plasma as a predictor of mortality in patients with COVID-19. Heart Lung. 2021;50(2):329–333. doi: 10.1016/j.hrtlng.2021.01.016
15. Zhang L., Yan X., Fan Q., Liu H., Liu X., Liu Z., Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J. Thromb. Haemost. 2020;18(6):1324–1329. doi: 10.1111/jth.14859
16. Llitjos J.F., Leclerc M., Chochois C., Monsallier J.M., Ramakers M., Auvray M., Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J. Thromb. Haemost. 2020;18(7):1743–1746. doi: 10.1111/jth.14869
17. Ranucci M., Baryshnikova E., Anguissola M., Pugliese S., Falco M., Menicanti L. The long term residual effects of COVID-associated coagulopathy. Int. J. Mol. Sci. 2023;24(6):5514. doi: 10.3390/ijms24065514
18. Fan B.E., Wong S.W., Sum C.L.L., Lim G.H., Leung B.P., Tan C.W., Ramanathan K., Dalan R., Cheung C., Lim X.R., … COVID-19 Clotting and Bleeding Investigators. Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long-term outcomes in COVID-19 patients. Am. J. Hematol. 2022;97(7):915–923. doi: 10.1002/ajh.26575
19. Thachil J., Cushman M., Srivastava A. A proposal for staging COVID-19 coagulopathy. Res. Pract. Thromb. Haemost. 2020;4(5):731–736. doi: 10.1002/rth2.12372
Review
For citations:
Sevostyanova E.V., Nikolaev Yu.A., Polyakov V.Ya., Emelyanova I.L. Features of lipid metabolism and hemostasis in patients with arterial hypertension underwent a new coronavirus infection COVID-19. Сибирский научный медицинский журнал. 2024;44(5):181-186. (In Russ.) https://doi.org/10.18699/SSMJ20240521
Views:
797
Email this article 